ESCRS - Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute ;
ESCRS - Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute ;

Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute

Johnson & Johnson Medical GmbH has announced a definitive agreement to acquire German software company, Surgical Process Institute (SPI).

Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute
Colin Kerr
Colin Kerr
Published: Friday, October 20, 2017
  Johnson & Johnson Medical GmbH has announced a definitive agreement to acquire German software company, Surgical Process Institute (SPI), a leading specialist for the standardization and digitalization of surgical workflows in the operating theatre. SPI provides innovative software solutions designed to improve patient outcomes and operating room efficiency by reducing variability in surgical procedures. "At Johnson & Johnson Medical Devices Companies, we are committed to broadening our portfolio of products and services to meet the changing needs of our customers around the world," said Sandi Peterson, Group Worldwide Chair for Johnson & Johnson**. "SPI's unique offerings have been shown to reduce surgery variability and the time spent in the operating room.  These new digital tools will allow us to deliver a more comprehensive and effective solution for our customers and help them continue to improve patient care."   "Our aim is to establish optimal medical standards in surgery, so that patients have access to the best treatment no matter where they are undergoing surgery," says Gunter Trojandt, Managing Director Surgical Process Institute. "We have products already in use in a significant number of larger hospitals in Germany and further projects are underway in GermanySwitzerland and the Nordic Countries." SPI´s products will be available in Europe, the Middle East and Africa through Johnson & Johnson Medical Devices companies in 2018 . Pilots across all other regions will start in 2018 aiming for full worldwide product availability in 2019.
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;